Pfizer and Flynn Pharma have been fined a complete of 70 million kilos ($84 million) on Thursday by Britain’s antitrust watchdog for overcharging the National Health Services (NHS) for a life-saving epilepsy drug,
The Competition and Markets Authority (CMA) in 2016 had fined Pfizer and Flynn about 90 million kilos for inflating costs for Epanutin by as a lot as 2,600% to 67.50 kilos for a 100mg pack earlier than the businesses received a 2018 attraction towards the penalty.
The Competition Appeal Tribunal had referred the matter again to the CMA, which in August 2021 caught to its view that the 2 corporations broke the legislation.
In September 2012, Pfizer offered the UK distribution rights for Epanutin to Flynn. Before that, Pfizer was promoting phenytoin sodium capsules to UK wholesalers and pharmacies. Both Pfizer and Flynn Pharma mentioned they intend to attraction the CMA choice. “Surprised and disappointed at the Competition and Markets Authority (CMA) issuance of a further (second) Decision finding an abuse of competition law on the part of Flynn,” the corporate mentioned in a press release emailed to Reuters.
Epanutin is a life-saving drug which is used to regulate a wide range of epileptic situations, or forestall seizures throughout or after mind surgical procedure or extreme head harm. The regulator added that the corporations have been overcharging for greater than 4 years.
It mentioned that spending by Britain’s NHS on the capsules, containing phenytoin sodium, jumped to about 50 million kilos in 2013 from about 2 million kilos a yr earlier.